On Mar. 24, 2021, AXIM Biotechnologies announced that partner Empowered Diagnostics, had filed an Emergency Use Authorization or EUA application with the US Food and Drug Administration (FDA) for the approval to use ImmunoPass, the company’s rapid test that semi-quantitatively measures levels of COVID-19 neutralizing antibodies, to detect COVID-19 neutralizing antibodies in whole blood at point-of-care locations.

AXIMsaid earlier this month that it had completed clinical trials, identifying that operators found ImmunoPass easy to use and that they encountered no issues in using the company’s test to measure participants’ levels of COVID-19 neutralizing antibodies.